Pfizer 2007 Annual Report Download - page 21

2007 Financial Report 19
Financial Review
Pfizer Inc and Subsidiary Companies
in Japan in July 2006 for the indications of depression/depressed
state and panic disorder.
On May 2, 2007, the FDA proposed that the existing blackbox
warning on the labels of all antidepressants, including Zoloft,
which describes an increased risk of suicidal thoughts and
behavior in some children and adolescents, be expanded to
include young adults to age 24, particularly during the first two
months of treatment. The proposed label change also states
that studies have not shown this increased risk in adults older
than 24, that adults age 65 and older who are treated with
antidepressants have a decreased risk of suicidal thoughts and
behavior, and that depression and certain other psychiatric
disorders are themselves the most important causes of suicide.
We have implemented this label change in accordance with the
FDA’s proposal.
•Geodon/Zeldox, a psychotropic agent, is a dopamine and
serotonin receptor antagonist indicated for the treatment of
schizophrenia and acute manic or mixed episodes associated
with bipolar disorder. It is available in both an oral capsule and
rapid-acting intramuscular formulation. In the U.S., Geodon had
a new prescription share of 6.7% for 2007. In 2007, Geodon
worldwide revenues grew 13%, compared to 2006. Geodon
growth was driven by recognition of its efficacy by prescribers
as clinical experience increased, and by a favorable metabolic
profile.
•Lyrica grew to a 10.9% new prescription share of the total U.S.
anti-epileptic market in 2007, fueled by strong efficacy, as well
as high physician and patient satisfaction. In June 2007, Lyrica
was approved in the U.S. for the management of fibromyalgia,
one of the most common chronic, widespread pain conditions.
This approval represents a breakthrough for the more than six
million Americans who suffer from this debilitating condition
who previously had no FDA-approved treatment.
•Celebrex was approved in Japan in January 2007, for the
treatment of osteoarthritis and rheumatoid arthritis. In February
2007, Celebrex was approved in Europe for the treatment of
ankylosing spondylitis. From April 2007 through July 2007, we
ran an innovative Celebrex direct-to-consumer (DTC) television
advertising campaign in the U.S. about treatment options for
arthritis. The 21⁄2-minute television advertisement opened by
addressing cardiovascular (CV) safety first and clarifying
misperceptions among arthritis sufferers about the risks and
benefits of Celebrex and other prescription non-steroidal anti-
inflammatory drugs. This DTC ad campaign helped to generate
patient interest and initiate a productive dialogue between
physicians and patients. We resumed this television advertising
campaign in November 2007.
See Notes to Consolidated Financial Statements—Note 20.
Legal Proceedings and Contingencies for a discussion of recent
developments with respect to certain patent litigation relating
to Celebrex.
•Zyvox is the world’s best-selling branded medicine for serious
gram-positive infections in adults and children, which
increasingly are caused by drug-resistant bacteria in hospitals
and more recently, in the community setting. Zyvox is an
appropriate first-line therapy for patients with serious
complicated skin and skin structure infections or nosocomial
pneumonia known or suspected to be caused by gram-positive
pathogens, including Methicillin-resistant Staphylococcus aureus
(MSRA) infection, with the flexibility of an intravenous and oral
regimen. Zyvox works with a unique mechanism of action,
which minimizes the potential for cross-resistance with other
antibiotic classes and thus has the potential to effectively treat
MRSA infection despite growing resistance to other important
antibiotics. Worldwide sales of Zyvox grew 21 % to $944 million
in 2007.
•Zithromax/Zmax, for the treatment of bacterial infections,
experienced a 31% decline in worldwide revenues in 2007
compared to 2006, reflecting the expiration of Zithromax’s
composition-of-matter patent in the U.S. in November 2005 and
the end of Pfizer’s active sales promotion in July 2005.
•Selzentry/Celsentri (maraviroc) is the first in a new class of oral
HIV medicines in more than a decade known as CCR5 antagonists.
CCR5 antagonists work by blocking the CCR5 co-receptor, the
virus’ predominant entry route into T-cells. Selzentry/Celsentri
stops the R5 virus on the outside surface of the cells before it
enters, rather than fighting the virus inside, as do all other
classes of oral HIV medicines. Selzentry/Celsentri was approved
in the U.S. in August 2007 and in Europe in September 2007, and
is indicated for combination anti-retroviral treatment of
treatment-experienced adults infected with only CCR5-tropic
HIV-1 detectable, who have evidence of viral replication and have
HIV-1 strains resistant to multiple anti-retroviral agents. A
diagnostic test confirms whether a patient is infected with CCR5-
tropic HIV-1, which is also known as “R5-virus.”
•Viagra remains the leading treatment for erectile dysfunction
and one of the world’s most recognized pharmaceutical brands.
Viagra revenues grew 6% worldwide, with U.S. revenues flat
and international revenues increasing 13% in 2007, compared
to 2006. The growth in Viagra international revenues was
driven by foreign exchange, as well as a combination of other
factors, including our focus on strengthening its value
proposition to key customers and growth in the erectile
dysfunction market. In July 2007, we launched a television ad
campaign in the U.S. for Viagra aimed at educating and
motivating men with erectile dysfunction to seek treatment.
•Detrol/Detrol LA, a muscarinic receptor antagonist, is the most
prescribed medicine worldwide for overactive bladder, a
condition that affects up to 100 million people around the
world. Detrol/Detrol LA is an extended-release formulation
taken once daily. Worldwide Detrol/Detrol LA revenues grew
8% to $1.2 billion in 2007, compared to 2006. Detrol/Detrol LA
continues to lead the overactive bladder market and perform
well in an increasingly competitive marketplace. In the U.S.,
Detrol/Detrol LA’s new prescription share declined 3.4% to a
39.5% share for 2007.
See Notes to Consolidated Financial Statements—Note 20.
Legal Proceedings and Contingencies for a discussion of recent
developments with respect to certain patent litigation relating
to Detrol/Detrol LA.